Device- and endoscopic-therapy summary: Some endoscopic and device therapies have regulatory approvals and randomized-trial evidence for short-term efficacy but important device-specific safety signals and durability limitations. The Orbera intragastric balloon (IGB) is FDA-approved (Orbera indicated for adults BMI ≥ 30 and ≤ 40; maximum placement 6 months) and meets ASGE PIVI thresholds in pooled analyses (%EWL at 12 months ~25.44%, pooled %TWL ~13% at 6 months), but long-term maintenance of weight loss is uncertain and AEs / early removals are common; societies recommend concomitant lifestyle programs and PPI prophylaxis during IGB therapy.
TransPyloric Shuttle (TPS) and other transoral endoscopic devices: The TPS received FDA PMA (April 18, 2019) for adults with BMI 35.0–40.0 or 30.0–34.9 with comorbidity; evidence includes small RCTs and case series demonstrating short-term weight loss but requiring independent confirmation and longer follow-up — overall evidence is inconclusive and safety/ durability data are limited.
Gastrointestinal liners / DJBL (EndoBarrier): DJBL studies show superior short-term weight and cardiometabolic effects in some trials/cohorts but have significant safety concerns (including hepatic abscess, GI hemorrhage, device obstruction) and high early explant rates (e.g., cohort with 31% early explant and AE ~17%); NICE and other guidance restrict use to research settings.
Gastric electrical stimulation (GES), vagus nerve blocking (vBloc), and other implantable neurostimulation: Trials show modest weight-loss signals and some metabolic effects (e.g., Exilis/CLGES and ReCharge/vBloc), but mixed efficacy on prespecified endpoints and limited durability; implant-site pain, heartburn/dyspepsia, lead/system complications and device replacements are reported, and further robust RCTs with longer follow-up are recommended.
Aspiration therapy and bariatric artery embolization (BAE): Aspiration therapy (AspireAssist) has randomized and extension data demonstrating clinically meaningful TBWL maintained up to several years in selected cohorts (pooled SAE ~4.1%); BAE RCTs show modest short-term TBWL (example: 7.4 kg vs 3.0 kg at 6 months) but require larger trials to define durability and safety.
Transoral and endoscopic suturing (ESG/OverStitch): ESG produces clinically significant but generally lower weight loss than LSG in RCTs/observational comparisons (short-to-mid term), with SAE rates reported in the low single digits (~2%); longer-term comparative data are limited.
Regulatory and society-position context: Several devices have specific FDA clearances (e.g., Orbera, TPS) or IDE/CE history (DJBL) and societies (ASGE, ASMBS, AGA, NICE) provide conservative recommendations — endorsing use as adjuncts or within research frameworks where evidence/safety concerns persist. Overall, device choice requires informed consent about device-specific risks (spontaneous deflation, bowel obstruction, hepatic abscess, implant-site pain, lead failure) and planning for follow-up and adjunctive lifestyle/pharmacologic therapies.